Dantrolene
Dantrolene - Related Videos
01:26
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
0 Views •
2023
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles. The binding of dantrolene to the RYR1...
08:41
Monitoring Endoplasmic Reticulum Calcium Homeostasis Using a Gaussia Luciferase SERCaMP
0 Views •
Cited by 8 •
2015
Endoplasmic reticulum calcium homeostasis is disrupted in diverse pathologies. A secreted ER calcium monitoring protein (SERCaMP) reporter can be used to detect disruptions in the ER calcium store. This protocol describes the use of a Gaussia luciferase SERCaMP to examine ER calcium homeostasis in vitro and in vivo.
09:10
A Method for Culturing Embryonic C. elegans Cells
0 Views •
Cited by 13 •
2013
We describe here a revised protocol for large-scale culture of embryonic C. elegans cells. Embryonic C. elegans cells cultured in vitro using this method, appear to differentiate and recapitulate the expression of genes in a cell specific manner. Techniques that require direct access to the cells or isolation of specific cell types from the other tissues can be applied on C. elegans cultured cells.
FAQs
Dantrolene acts at ryanodine receptor 1, or RyR1, in the sarcoplasmic reticulum of skeletal muscle. By inhibiting this receptor, it limits the release of stored calcium into the muscle cell. That reduction interrupts the intracellular signal required for sustained contraction, making RyR1 a pharmacological link between abnormal calcium release and excessive muscle activity.
Reduced calcium availability decreases activation of the actin-myosin contractile system. As abnormal contraction falls, skeletal muscle generates less mechanical activity and less associated heat. This explains why dantrolene can address both major features of malignant hyperthermia, muscle rigidity and excessive heat production, rather than merely producing generalized muscle relaxation.
RyR1 is important because it controls calcium release from the skeletal-muscle sarcoplasmic reticulum, placing it near the start of the abnormal contraction pathway. Targeting this receptor allows dantrolene to reduce the intracellular event driving the reaction. The mechanism illustrates how pharmacology can intervene directly in disturbed muscle physiology instead of acting only on its downstream effects.
The drug provides a clear example of intracellular calcium regulation serving as a therapeutic target. In skeletal muscle, calcium release activates actin-myosin interaction; restricting that release reduces contraction and its consequences. This relationship helps pharmacology students connect receptor-level modulation at RyR1 with observable clinical changes, including reduced rigidity and relief of abnormal heat generation.
Dantrolene is used when malignant hyperthermia develops as a life-threatening reaction to certain anesthetics. Its relevance comes from addressing the underlying skeletal-muscle disturbance: RyR1 inhibition reduces calcium release, abnormal contraction, and heat production. In this setting, the medication represents a targeted treatment for an acute pharmacological emergency rather than routine muscle relaxation.
For chronic spasticity, dantrolene is used in selected patients to reduce persistent abnormal skeletal-muscle contraction. This differs from malignant hyperthermia, where the drug addresses an acute, life-threatening reaction associated with certain anesthetics. The two applications share the same muscle-calcium mechanism but differ in clinical context, time course, and therapeutic purpose.
During malignant hyperthermia, treatment aims to reverse the muscle rigidity and heat-producing process caused by excessive calcium release. In selected chronic spasticity cases, the goal is sustained reduction of abnormal muscle contraction. These outcomes reflect the same pharmacological action at RyR1, applied either to an emergency disturbance or a longer-term motor problem.